Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 68951

Tuesday, 11/25/2008 10:42:14 AM

Tuesday, November 25, 2008 10:42:14 AM

Post# of 257253
ghmm et al: An anomaly in the Boceprevir SPRINT-1 data:

The SVR rate in the “4+44” arm as reported in yesterday’s PR was 75%.

The SVR12 rate in this same trial arm as reported at AASLD was 74% (#msg-33283156).

Something’s wrong here because SVR, by definition, cannot be higher than SVR12!

I presume that the discrepancy stems from the re-inclusion in the SVR data set of one responder who was excluded from the SVR12 data set.

Did any analysts pick up on this anomaly during the webcast?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now